Active	Status	Sponsor type	Region	Phase	Filter
15 Active 4 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Xiaoyan
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis	Recruiting	3	402	RoW	Vedolizumab IV, Placebo	Takeda	Moderately to Severely Active Ulcerative Colitis	05/28	07/28
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice	Completed	N/A	500	RoW		Takeda	Colitis, Ulcerative, Crohn Disease	07/24	07/24